Sensitivity of older patients to antipsychotic motor side effects: A PET study examining potential mechanisms

American Journal of Geriatric Psychiatry

Volumn 17, Issue 3, 2009, Pages 255-263

  Uchida, Hiroyuki ^a,b   Kapur, Shitij ^c,d   Mulsant, Benoit H ^a,b   Graff Guerrero, Ariel ^a,d   Pollock, Bruce G ^a,b,d   Mamo, David C ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

Aging; Antipsychotic; Dopamine; Extrapyramidal side effects; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; LORAZEPAM; METHADONE; PALIPERIDONE; PAROXETINE; RACLOPRIDE C 11; RISPERIDONE; SERTRALINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BINDING KINETICS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG SENSITIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 67649283706     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318198776d     Document Type: Article

References (40)

1. Uchida H, Suzuki T, Mamo DC, et al: Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 2008; 16:584-593
2. Finkelstein E, Prabhu M, Chen H: Increased prevalence of falls among elderly individuals with mental health and substance abuse conditions. Am J Geriatr Psychiatry 2007; 15:611-619
3. Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 1961; 25:102-108
4. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943
5. Hollis J, Grayson D, Forrester L, et al: Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007; 15:932-941
6. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1081-1090
7. 2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15:19S-23S
8. Kapur S, Zipursky R, Jones C, et al: Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520
9. 2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008; 33:298-304
10. 2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161:818-825
11. Reardon GT, Rifkin A, Schwartz A, et al: Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 1989; 146:726-729
12. 2-like dopamine receptors: theory, validation, and changes during normal aging. J Cereb Blood Flow Metab 1997; 17:316-330
13. 2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997; 17:331-342
14. Uchida H, Mamo DC, Mulsant BH, et al: Why do the elderly need lower doses of antipsychotics? - evidence and mechanisms. J Clin Psychiatry, in press
15. Mauri MC, Volonteri LS, Colasanti A, et al: Clinical pharmacokinetics of atypical antipsychotics : a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46:359-388
16. Toornvliet R, van Berckel BN, Luurtsema G, et al: Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006; 79:540-548
17. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994
18. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
19. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
20. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
21. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
22. Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976
23. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. NeuroImage 1996; 4:153-158
24. Innis RB, Cunningham VJ, Delforge J, et al: Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27:1533-1539
25. 2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol 1998; 18:82-83
26. 2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869-875
27. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
28. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
29. Boulton DW, DeVane CL, Liston HL, et al: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71:163-169
30. List S, Seeman P: Neuroleptic/dopamine receptors: elevation and reversal. Adv Biochem Psychopharmacol 1980; 24:95-101
31. Seeman P, Bzowej NH, Guan HC, et al: Human brain dopamine receptors in children and aging adults. Synapse 1987; 1:399-404
32. Mamo DC, Sweet RA, Mulsant BH, et al: Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: a prospective double-blind study in depressed elderly patients. Am J Geriatr Psychiatry 2000; 8:226-231
33. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978; 135:1409-1410
34. Brans RG, van Haren NE, van Baal GC, et al: Longitudinal MRI study in schizophrenia patients and their healthy siblings. Br J Psychiatry 2008; 193:422-423
35. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987; 1:5-15
36. 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000; 152:174-180
37. 2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res 1992; 575:47-56
38. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155:921-928
39. Meltzer CC, Leal JP, Mayberg HS, et al: Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990; 14:561-570
40. Leroy C, Comtat C, Trebossen R, et al: Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med 2007; 48:538-546